This list is based on the watchlists of people on Stock Events who follow M62.F. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
FAQs
What is Nyrada stock price today?▼
The current price of M62.F is €0.29 EUR — it has increased by +7.46% in the past 24 hours. Watch Nyrada stock price performance more closely on the chart.
What is Nyrada stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Nyrada stocks are traded under the ticker M62.F.
What is Nyrada market cap?▼
Today Nyrada has the market capitalization of 71.16M
What is Nyrada revenue for the last year?▼
Nyrada revenue for the last year amounts to 1.46M EUR.
What is Nyrada net income for the last year?▼
M62.F net income for the last year is -2.8M EUR.
How many employees does Nyrada have?▼
As of November 3, 2026, the company has 4,000 employees.
In which sector is Nyrada located?▼
Nyrada operates in the Health & Wellness sector.
When did Nyrada complete a stock split?▼
Nyrada has not had any recent stock splits.
Where is Nyrada headquartered?▼
Nyrada is headquartered in Sydney, United States.